Skip to main content
Top
Published in: BMC Neurology 1/2020

Open Access 01-12-2020 | Research article

Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study

Authors: Marlise E. A. van Eersel, Sipke T. Visser, Hanneke Joosten, Ron T. Gansevoort, Joris P. J. Slaets, Gerbrand J. Izaks

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Lowering vascular risk is associated with a decrease in the prevalence of cardiovascular disease and dementia. However, it is still unknown whether lowering of vascular risk with pharmacological treatment preserves cognitive performance in general. Therefore, we compared the change in cognitive performance in persons with and without treatment of vascular risk factors.

Methods

In this longitudinal observational study, 256 persons (mean age, 58 years) were treated for increased vascular risk during a mean follow-up period of 5.5 years (treatment group), whereas 1678 persons (mean age, 50 years) did not receive treatment (control group). Cognitive performance was three times measured during follow-up using the Ruff Figural Fluency Test (RFFT) and Visual Association Test (VAT), and calculated as the average of standardized RFFT and VAT score per participant. Because treatment allocation was nonrandomized, additional analyses were performed in demographic and vascular risk-matched samples and adjusted for propensity scores.

Results

In the treatment group, mean (SD) cognitive performance changed from − 0.30 (0.80) to − 0.23 (0.80) to 0.02 (0.87), and in control group, from 0.08 (0.77) to 0.24 (0.79) to 0.49 (0.74) at the first, second and third measurement, respectively (ptrend < 0.001). After adjustment for demographics and vascular risk, the change in cognitive performance during follow-up was not statistically significantly different between the treatment and control group: mean estimated difference, − 0.10 (95%CI − 0.21 to 0.01; p = 0.08). Similar results were found in matched samples and after adjustment for propensity score.

Conclusion

Change in cognitive performance during follow-up was similar in treated and untreated persons. This suggests that lowering vascular risk preserves cognitive performance.
Appendix
Available only for authorised users
Literature
2.
go back to reference Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12:267–77.CrossRef Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12:267–77.CrossRef
3.
go back to reference Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.CrossRef Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.CrossRef
4.
go back to reference The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553–61.CrossRef The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553–61.CrossRef
5.
go back to reference Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010;6:775–85.CrossRef Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010;6:775–85.CrossRef
6.
go back to reference Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd-Jones DM, et al. Defining optimal brain health in adults. A presidential advisory from the American Heart Association / American Stroke Association. Stroke. 2017;48:e248–303.CrossRef Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd-Jones DM, et al. Defining optimal brain health in adults. A presidential advisory from the American Heart Association / American Stroke Association. Stroke. 2017;48:e248–303.CrossRef
7.
go back to reference ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef
8.
go back to reference Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRef
9.
go back to reference Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63.CrossRef Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63.CrossRef
10.
go back to reference Moll van Charante EP, Richard E, Eurelings LS, van Dalen JW, Ligthart SA, van Bussel EF, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388:797–805.CrossRef Moll van Charante EP, Richard E, Eurelings LS, van Dalen JW, Ligthart SA, van Bussel EF, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388:797–805.CrossRef
11.
go back to reference Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–89.CrossRef Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–89.CrossRef
12.
go back to reference van Eersel MEA, Joosten H, Gansevoort RT, Slaets JPJ, Izaks GJ. Treatable vascular risk and cognitive performance in persons aged 35 years or older: longitudinal study of six years. J Prev Alzheimers Dis. 2019;6(1):42–9.PubMed van Eersel MEA, Joosten H, Gansevoort RT, Slaets JPJ, Izaks GJ. Treatable vascular risk and cognitive performance in persons aged 35 years or older: longitudinal study of six years. J Prev Alzheimers Dis. 2019;6(1):42–9.PubMed
14.
go back to reference Dorresteijn JA, Kaasenbrood L, Cook NR, van Kruijsdijk RC, van der Graaf Y, Visseren FL, et al. How to translate clinical trial results into gain in healthy life expectancy for individual patients. BMJ. 2016;352:i1548.CrossRef Dorresteijn JA, Kaasenbrood L, Cook NR, van Kruijsdijk RC, van der Graaf Y, Visseren FL, et al. How to translate clinical trial results into gain in healthy life expectancy for individual patients. BMJ. 2016;352:i1548.CrossRef
15.
go back to reference van Eersel ME, Joosten H, Koerts J, Gansevoort RT, Slaets JP, Izaks GJ. Longitudinal study of performance on the Ruff figural fluency test in persons aged 35 years or older. PLoS One. 2015;10:e0121411.CrossRef van Eersel ME, Joosten H, Koerts J, Gansevoort RT, Slaets JP, Izaks GJ. Longitudinal study of performance on the Ruff figural fluency test in persons aged 35 years or older. PLoS One. 2015;10:e0121411.CrossRef
16.
go back to reference Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301:1790–7.CrossRef Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301:1790–7.CrossRef
17.
go back to reference Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT, et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol. 2008;168:897–905.CrossRef Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT, et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol. 2008;168:897–905.CrossRef
18.
go back to reference Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ. The population-based prescription database IADB.Nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13:285–92.CrossRef Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ. The population-based prescription database IADB.Nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13:285–92.CrossRef
19.
go back to reference Ruff R, Light R, Evans R. The Ruff figural fluency test: a normative study with adults. Dev Neuropsychol. 1987;3:37–51.CrossRef Ruff R, Light R, Evans R. The Ruff figural fluency test: a normative study with adults. Dev Neuropsychol. 1987;3:37–51.CrossRef
20.
go back to reference Ruff R. Ruff figural fluency test: professional manual. Lutz, FL: Psychological Assessment Resources, Inc.; 1996. Ruff R. Ruff figural fluency test: professional manual. Lutz, FL: Psychological Assessment Resources, Inc.; 1996.
21.
go back to reference Izaks GJ, Joosten H, Koerts J, Gansevoort RT, Slaets JP. Reference data for the Ruff figural fluency test stratified by age and educational level. PLoS One. 2011;6:e17045.CrossRef Izaks GJ, Joosten H, Koerts J, Gansevoort RT, Slaets JP. Reference data for the Ruff figural fluency test stratified by age and educational level. PLoS One. 2011;6:e17045.CrossRef
22.
go back to reference Lindeboom J, Schmand B. Visual association test. Manual. The Netherlands: PITS B V Leiden; 2003. Lindeboom J, Schmand B. Visual association test. Manual. The Netherlands: PITS B V Leiden; 2003.
24.
go back to reference D'Agostino RBS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.CrossRef D'Agostino RBS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.CrossRef
25.
go back to reference Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63.CrossRef Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63.CrossRef
26.
go back to reference Schilling C, Mortimer D, Dalziel K, Heeley E, Chalmers J, Clarke P. Using classification and regression trees (CART) to identify prescribing thresholds for cardiovascular disease. Pharmacoeconomics. 2016;34:195–205.CrossRef Schilling C, Mortimer D, Dalziel K, Heeley E, Chalmers J, Clarke P. Using classification and regression trees (CART) to identify prescribing thresholds for cardiovascular disease. Pharmacoeconomics. 2016;34:195–205.CrossRef
27.
go back to reference Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment. Med Decis Making. 2012;32:498–506.CrossRef Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment. Med Decis Making. 2012;32:498–506.CrossRef
28.
go back to reference De Jong PE, Hillege HL, Pinto-Sietsma SJ, de Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects a risk for progressive renal failure in an early phase? Nephrol Dial Transplant. 2003;18:10–3.CrossRef De Jong PE, Hillege HL, Pinto-Sietsma SJ, de Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects a risk for progressive renal failure in an early phase? Nephrol Dial Transplant. 2003;18:10–3.CrossRef
29.
go back to reference Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJG, et al. Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol. 2011;6:1400–9.CrossRef Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJG, et al. Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol. 2011;6:1400–9.CrossRef
30.
go back to reference Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJG, Slaets JP, et al. Statin use and cognitive function: population-based observational study with long term follow-up. PLoS One. 2015;10:e0118045.CrossRef Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJG, Slaets JP, et al. Statin use and cognitive function: population-based observational study with long term follow-up. PLoS One. 2015;10:e0118045.CrossRef
31.
go back to reference Gillette Guyonnet S, Van Kan A, Andrieu S, Aquino JP, Arbus C, Becq JP, et al. Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA task force). J Nutr Health Aging. 2008;12(8):520–9.CrossRef Gillette Guyonnet S, Van Kan A, Andrieu S, Aquino JP, Arbus C, Becq JP, et al. Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA task force). J Nutr Health Aging. 2008;12(8):520–9.CrossRef
32.
go back to reference Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493.CrossRef Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493.CrossRef
33.
go back to reference Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients? J Alzheimers Dis. 2012;32:765–72.CrossRef Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients? J Alzheimers Dis. 2012;32:765–72.CrossRef
34.
go back to reference Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, et al. Methodological challenges in designing dementia prevention trials - the European dementia prevention initiative (EDPI). J Neurol Sci. 2012;322:64–70.CrossRef Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, et al. Methodological challenges in designing dementia prevention trials - the European dementia prevention initiative (EDPI). J Neurol Sci. 2012;322:64–70.CrossRef
35.
go back to reference Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010;11:118–2202 11-118.CrossRef Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010;11:118–2202 11-118.CrossRef
36.
go back to reference Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol. 2012;26:543–70.CrossRef Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol. 2012;26:543–70.CrossRef
Metadata
Title
Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study
Authors
Marlise E. A. van Eersel
Sipke T. Visser
Hanneke Joosten
Ron T. Gansevoort
Joris P. J. Slaets
Gerbrand J. Izaks
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-01822-0

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue